Globe Life Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GL research report →
Range $165 – $215
Price Chart
About the company
Globe Life Inc. delivers diverse life insurance and supplementary health coverage, alongside annuity products, targeting households in the lower-middle to middle-income brackets throughout the United States. The company's operations are structured into four key segments: Life Insurance, Supplemental Health Insurance, Annuities, and Investments.
- CEO
- Frank Martin Svoboda
- IPO
- 1980
- Employees
- 3,695
- HQ
- McKinney, TX, US
Get TickerSpark's AI analysis on GL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $11.44B
- P/E
- 10.04
- Fwd P/E
- 9.78
- PEG
- 1.01
- P/S
- 1.84
- P/B
- 1.81
- EV/EBITDA
- 23.88
- Div Yield
- 0.82%
- Gross Margin
- 21.19%
- Op Margin
- 9.14%
- Net Margin
- 18.88%
- ROE
- 19.09%
- ROIC
- 1.56%
Latest fiscal year · YoY change
- Revenue
- $6.00B+3.8%
- Gross Profit
- $2.00B+7.1%
- Op Income
- $1.46B
- Net Income
- $1.16B+8.4%
- EPS
- $14.30+19.3%
- OCF Growth
- -0.4%
- FCF Growth
- -5.8%
- 52W High
- $191.55
- 52W Low
- $129.21
- 50D MA
- $164.47
- 200D MA
- $161.07
- Beta
- 0.46
- RSI (14)
- 34
- Avg Volume
- 513.01K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Globe Life posted solid third-quarter earnings and premium growth, but management lowered 2026 EPS guidance because of United American margin pressure from CMS-related claim timing and Evri losses.· October 22, 2026
- Q3 net income was $361 million, or $4.62 per share, while net operating income was $379 million, or $4.84 per share; book value per share rose 23% year over year to $85.35 GAAP and $103.62 excluding AOCI.
- Total premium revenue grew 7% year over year; life premium revenue rose 2% to $865 million and health premium revenue rose 16% to $447 million.
- Management cut 2026 net operating EPS guidance to $15.35-$15.65 and said normalized EPS growth should be about 8% for 2026.
- American Income productivity improved, Liberty National agent count grew 9%, Family Heritage continued to show stronger retention/middle management, and management expects further sales improvement from compensation changes and higher health emphasis.
- United American results were hurt by about $7 million of excess Medicare supplement claims tied to CMS processing issues and about $16 million of underwriting loss at Evri, though management expects claims pressure to normalize and pricing actions to help.
Third-quarter net income was $361 million, or $4.62 per share, down 2% from $4.73 a year ago. Net operating income was $379 million, or $4.84 per share, up 1% from $4.81 a year ago. Total premium revenue grew 7% year over year. Life premium revenue rose 2% to $865 million, with life underwriting margin of $458 million, down 5% year over year; excluding assumption updates, life underwriting margin would have increased about 3%. Health premium revenue grew 16% to $447 million, and health underwriting margin increased 7% to $116 million. Administrative expenses were $95 million, up 6%, or 7.3% of premium. Excess investment income was $38 million, up 3%, with net investment income of $296 million, also up 3%. Management now expects full-year 2026 net operating EPS of $15.35-$15.65, down from prior guidance, and still expects full-year premium revenue growth around 6.5%, life premium growth of 2.5%-2.75%, health premium growth around 15%, and administrative expenses at about 7.3% of premium. For 2027, guidance is net operating EPS of $16.10-$17.10, premium revenue growth of 6%-8%, life premium growth of 4%, and health premium growth of 13%-15%.
Frank Svoboda emphasized that the quarter reflected favorable long-term assumption updates, even though reported results were mixed by segment. He framed the business as continuing to benefit from favorable claims experience, premium growth, and strong capital flexibility, while also noting specific pressure points at United American and the need to adapt through AI, digital changes, and strategic reinsurance. His tone was constructive and steady, with repeated emphasis on operational discipline and long-term positioning.
Tom Kalmbach focused on capital, reserves, and guidance updates. He said the quarter included an overall reduction in policy obligations of about $120 million from life and health assumption changes, maintained that the company’s long-duration bond portfolio remains manageable despite a $2.7 billion unrealized loss, and noted invested assets of $22.3 billion. On capital returns, he said the parent ended the quarter with about $110 million of liquid assets, repurchased about 1.1 million shares for $185 million at an average price of $175.61, and returned about $210 million to shareholders in the quarter. He also said 2027 parent excess cash flow could be about $850 million to $950 million, with share repurchases still the primary use of excess cash after dividends.
Analysts pressed management on how much of the 2027 EPS guidance assumes assumption-update benefits, and management declined to quantify it, saying the range embeds multiple scenarios and that they want more Q4 experience before narrowing it. Questions also focused on Evri’s volatility and whether the business makes long-term strategic sense; management said it offers broker/product synergies, but it is still a startup with lumpy results and is not expected to be a major share of health underwriting margin. On the CMS issue, management said the claim delays largely stemmed from Medicare ID and billing-rate processing issues, that the main effect hit Q3, and that related claims should feed into 2027 rate filings. Analysts also asked about American Income recruiting and productivity, and management said the recent compensation changes improved productivity and stabilized agent count, with additional changes planned later this year to support 2027 sales growth.
The core insurance franchises still showed growth, with premium revenue up across life and health and strong health sales at United American and Family Heritage. Management also expressed confidence that compensation changes, agent count growth, rate actions, and additional AI/digital investments can support better sales and expense leverage over time. Capital returns also remain sizable, with a higher 2027 excess cash flow outlook and continued buybacks as the main use of excess parent cash.
The main downside this quarter was margin pressure from United American, where CMS-related timing and high-severity claims at Evri pushed health margins below target. Management also acknowledged that Evri is still volatile, could have additional losses in 2027, and is not yet at a scale where results are stable. In addition, DTC sales were down as digital advertising and search behavior shifted, and American Income still needs more recruiting progress to sustain stronger sales growth.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.1%
- Shares Outstanding
- 75.44M
- Float Shares
- 74.76M
of shares held by institutions
719 13F filers
Buy/sell ratio 0.25. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for GL, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Alan ArmstrongSenate | Buy | Mar 27, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Jan 13, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Jan 29, 26 | Filing → |
| Lisa C. McClainHouse · MI09 | Sell | Jul 10, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Buy | Jun 17, 25 | Filing → |
| Susan Margaret CollinsSenate · ME | Sell | Aug 5, 24 | Filing → |
| Lois FrankelHouse · FL22 | Sell | Sep 8, 23 | Filing → |
| Lois FrankelHouse · FL22 | Sell | Jun 2, 23 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 10.09M | ▲ 86.35K |
| Blackrock, Inc. | 5.51M | ▼ 22.03K |
| Vanguard Capital Management LLC | 5.03M | ▼ 50.16K |
| Invesco Ltd. | 5.02M | ▲ 400.87K |
| Vanguard Portfolio Management LLC | 4.13M | ▼ 52.68K |
| State Street Corp | 3.52M | ▼ 218.40K |
| Pzena Investment Management LLC | 3.48M | ▲ 2.12M |
| Geode Capital Management, LLC | 2.73M | ▼ 71.89K |
| Dimensional Fund Advisors LP | 2.48M | ▲ 86.41K |
| Morgan Stanley | 1.86M | ▼ 78.57K |
| Nuveen, LLC | 1.60M | ▲ 103.90K |
| Arrowstreet Capital, Limited Partnership | 1.53M | ▲ 89.28K |
Held by 935 ETFs
Biggest fund positions in GL by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 11, 26 | Zorn Rebecca E | other | 1,000 |
| Nov 11, 26 | Zorn Rebecca E | sell | 1,000 |
| Nov 11, 26 | Zorn Rebecca E | other | 166 |
| Nov 11, 26 | Zorn Rebecca E | other | 1,000 |
| Mar 2, 26 | Hensley Robert Edward | sell | 2,569 |
| Oct 23, 26 | MAJORS MICHAEL CLAY | sell | 14,377 |
| Sep 22, 26 | Hensley Robert Edward | other | 10,000 |
| Sep 22, 26 | Hensley Robert Edward | other | 10,000 |
| Sep 22, 26 | Hensley Robert Edward | sell | 3,344 |
| Sep 22, 26 | Hensley Robert Edward | sell | 6,656 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our GL coverage
Recent articles, reports, and earnings notes.

Globe Life (GL): Disciplined Growth at a Reasonable Price
Globe Life is a steady compounder with improving health growth, strong cash generation, and a valuation that still looks reasonable versus earnings power.

Globe Life (GL): Cash-Generative Buyback Compounder
Globe Life is a disciplined insurer with steady premium growth, strong underwriting margins, and meaningful buyback support. The stock still looks undervalued relative to its earnings power and 2026 guidance.

Globe Life Inc. (GL) falls 10% after hours on earnings jitters
Globe Life Inc. (GL) falls sharply in after-hours trading, erasing a chunk of recent gains near its 52-week high. The move appears tied more to earnings positioning and profit-taking than to a fresh company-specific headline, leaving investors focused on the upcoming April 22 report.
Want a deeper read on GL?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Why Is Globe Life (GL) Down 8.8% Since Last Earnings Report?
zacks.com · Nov 20
GL Stock Gains 22.3% in a Year: Here's What Investors Should Know
zacks.com · Nov 16
Globe Life Inc. (GL) – What Are Researchers Thinking About This Stock?
defenseworld.net · Nov 6
GLOBE LIFE INC. DECLARES DIVIDEND
prnewswire.com · Nov 5
5 Accident & Health Insurers to Watch Despite Cost Pressure
zacks.com · Nov 5
Globe Life: 3 Key Takeaways for Long-Term Investors
fool.com · Oct 30
Did Globe Life Inc. Insiders Breach their Fiduciary Duties to Shareholders?
prnewswire.com · Oct 27
Globe Life (NYSE:GL) EVP Michael Clay Majors Sells 14,377 Shares of Stock
defenseworld.net · Oct 27
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.